Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Pharmacokinetics of SD-0542, a Novel Histone Deacetylase Inhibitor, in Rats

  • Published : 2005.10.20
Download PDF
⟨ Previous Next ⟩

Abstract

This study reports the pharmacokinetics of a novel histone deacetylase inhibitor, SD-0542, in rats after i..v. and oral administration. SD-0542 was injected intravenously at doses of 10, 20, and 40 mg/kg. The terminal elimination half-life $(t_{1/2})$, systemic clearance (Cl), and steady-state volume of distribution $(V_{ss})$ remained unaltered as a function of dose, with their values ranging from 2.0-2.5 hr, 157.2-214.1 ml/min/kg, and 11.1-17.5 L/kg, respectively, whereas, the initial serum concentration $(C_0)$ and AUC increased linearly as the dose was increased. Renal excretion of SD-0542 was minimal. Oral pharmacokinetic studies were conducted in rats at a dose of 20 mg/kg. The $T_{max}$, Cl/F, $V_{z}/F$, and $t_{1/2}$ were 2.0 hr, 92864 ml/min/kg, 16331 L/kg, and 2.0 hr, respectively. Taken together, SD-0542 showed linear pharmacokinetics over the i.v. bolus dose range studied. SD-0542 was poorly absorbed, with the absolute oral bioavailability of 0.9%.

Keywords

References

  1. P.T. Meinke and P. Liberator, Histone deacetylase: a target for antiproliferative and antiprotozoal agents, Curr. Med. Chem., 8, 211-235 (2001) https://doi.org/10.2174/0929867013373787
  2. P.A. Marks, V.M. Richon and R.A. Rifkind, Histone deacetylase inhibitors: inducers of diffierentiation or apoptosis of transformed cells, J. Natl. Cancer Inst., 92, 1210-1216 (2000) https://doi.org/10.1093/jnci/92.15.1210
  3. R. Pili, M.P. Kruszwski, B.W. Hager, J. Lantz and M.A. Carducci, Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis, Cancer Res., 61, 1477-1485 (2001)
  4. R. Furumai, Y. Komatsu, N. Nishino, S. Khochbin, M. Yoshida and S. Horinouchi, Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin, Proc. Natl. Acad.Sci. USA, 98, 87-92 (2001)
  5. O.H. Kramer, M. Gottlicher and T. Heinzel, Histone deacetylase as a therapeutic target, Trends Endocrin. Metab., 12, 294-300 (2001) https://doi.org/10.1016/S1043-2760(01)00438-6
  6. S.J. Darkin-Rattray, A.M. Gumett, R.W. Myers, P.M. Dulski, T.M. Crumley, J.J. Allocco, C. Cannova, P.T. Meinke, S.L. Colletti, M.A. Bednarek, S.B. Singh, M.A. Goetz, A.W. Dombrowski, J.D. Polishook and D.M. Schmatz, Apicidin: a noveI antiprotozoal agent that inhibits parasite histone deacetylase, Proc. Natl. Acad. Sci. USA, 93, 13143-13147 (1996)
  7. S.L. Colletti, R.W. Myers, S.J. Darkin-Rattray, A.M. Gumett, P.M. Dulski, S. Galuska, J.J. Allocco, M.B. Ayer, C. Li, J. Lim, T.M. Crumley, C. Cannova, D.M. Schmatz, M.J. Wyvratt, M.H. Fisher and P.T. Meinke, Broad spectrum antiprotozoal agents that inhibit histone deacetylase structure-activity relationships of apicidin. Part 1, Bioorg. Med. Chem. Lett., 11, 107-111 (2001) https://doi.org/10.1016/S0960-894X(00)00604-1
  8. J.W. Han, S.H. Ahn, S.H. Park, S.Y. Wang, G.U. Bae, D.W. Seo, H.K. Kwon, S. Hong, H.Y. Lee, Y.W. Lee and H.W. Lee, Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and Gelsolin1, Cancer Res., 60, 6068-6074 (2000)
  9. S.H. Kwon, S.H. Ahn, Y,K. Kim, G.U. Bae, J.W. Yoon, S. Hong, H.Y. Lee, Y.W. Lee, H.W. Lee, J.W. Han, Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells, J. Biol. Chem., 277, 2073-2080 (2002) https://doi.org/10.1074/jbc.M106699200
  10. S.H. Kim, S. Ahn, J.W. Han, H.W. Lee, H.Y. Lee, Y.W. Lee, M.R. Kim, K.W. Kim, W.B. Kim and S. Hong, Apicidin is a histone deacetylase inhibitor with anti-invasive and antiangiogenic potentials, Biochem. Biophy. Res. Commun., 315, 964-970 (2004) https://doi.org/10.1016/j.bbrc.2004.01.149
  11. S.B. Singh, D.L., Zink, J.M. Liesch, R.T. Mosley, A.W. Dombrowski, G.F. Bills, S.J. Darkin-Rattray, D.M. Schmatz and M.A. Goetz, Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal alpha-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities, J. Org. Chem., 67, 815-825 (2002) https://doi.org/10.1021/jo016088w
  12. B.S. Shin, J. Kim, C.H. Yoon, C.H. Kim, E.H. Park, J.W. Han and S.D. Yoo, Development of a liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of apicidin, a novel histone deacetylase inhibitor, in rat serum: application to a pharmacokinetic study, Rapid Commun. Mass Spectrom., 19, 408-414 (2005) https://doi.org/10.1002/rcm.1805
  13. K.K. Chan, R. Bakhtiar and C. Jiang, Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS, Invest. New Drugs, 15, 195-206 (1997) https://doi.org/10.1023/A:1005847703624